A 52-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and A beta-Specific Antibody Response Following Three Subcutaneous Injections of CAD106

Trial Profile

A 52-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and A beta-Specific Antibody Response Following Three Subcutaneous Injections of CAD106

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2013

At a glance

  • Drugs Amilomotide (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Sep 2011 Results presented at the 15th World Congress of Psychiatry.
    • 09 Jun 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top